Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Butane SCHEMBL2364882 | 0.90 | KDM4E (0.41) | NPC1CYP3A4KDM4EHTTPOLB | |
| Butane SCHEMBL2364965 | 0.89 | KDM4E (0.41) | NPC1CYP3A4KDM4EHTTPOLB | |
| SCHEMBL17930846 | 0.89 | KDM4E (0.43) | NPC1CYP3A4KDM4EHTTPOLB | |
| Butane SCHEMBL2364892 | 0.88 | KDM4E (0.40) | NPC1CYP3A4KDM4EHTTPOLB | |
| Butane SCHEMBL3896794 | 0.87 | KDM4E (0.40) | NPC1CYP3A4KDM4EHTTPOLB | |
| Butane SCHEMBL3273854 | 0.86 | KDM4E (0.42) | NPC1CYP3A4KDM4EHTTPOLB | |
| SCHEMBL14889404 | 0.86 | KDM4E (0.43) | NPC1CYP3A4KDM4EHTTPOLB | |
| SCHEMBL17930826 | 0.86 | KDM4E (0.43) | NPC1CYP3A4KDM4EHTTPOLB | |
| SCHEMBL12985731 | 0.85 | KDM4E (0.42) | NPC1CYP3A4KDM4EHTTPOLB | |
| SCHEMBL14889460 | 0.84 | KDM4E (0.41) | NPC1CYP3A4KDM4EHTTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050222133-A1 | PROCESS FOR PREPARING PYRROLO[2, 1-C] [1,4] BENZODIAZEPINE HYBRIDS | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH | 2005-10-06 | — | — | US | disclosed |
| US-6951853-B1 | Process for preparing pyrrolo[2, 1-c] [1,4] benzodiazepine hybrids | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2005-10-04 | — | — | US | disclosed |
| WO-2005063759-A1 | PROCESS FOR PREPARING PYRROLO[2, 1-c] [1, 4] BENZODIAZEPINE HYBRIDS | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2005-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222133-A1 | PROCESS FOR PREPARING PYRROLO[2, 1-C] [1,4] BENZODIAZEPINE HYBRIDS | PBRM1, GABRP, GABRA4 | NPC1 3020/4885CYP3A4 25/4885KDM4E 740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.